Inhibitory Anti-Tumor Effects of Interleukin-4 on Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia and Other Hematopoietic Malignancies

References

• Howard M., Farrar J., Hilfiker M., Johnson B., Takaku K., Hamaoka T., Pall W. E. Identification of a T-cell-derived B cell growth factor distinct from interleukin 2. The Journal Experimental Medicine 1982; 155: 914–23
   PubMed Web of Science ®Google Scholar
• Stein P., Dubois P., Greenblatt D., Howard M. Induction of antigen-specific proliferation in affinity-purified small B lymphocytes: Requirement for BSF-1 by type 2 but not type 1 thymus-independent antigens. The Journal of Immunology 1986; 136: 2080–9
   PubMed Web of Science ®Google Scholar
• Aaronson S. A. Growth factors and cancer. Science 1991; 254: 1146–53
   PubMed Web of Science ®Google Scholar
• Rennick D., Yang G., Muller-Sieburg C., Smith C., Arai N., Tanabe Y., Gemmell L. Interleukin 4 (B-cell stimulatory factor 1) can enhance or antagonize the factor-dependent growth of hematopoietic progenitor cells. Proceedings of National Academy of Science USA 1987; 84: 6889–93
   PubMed Web of Science ®Google Scholar
• Okabe M., Kuni-Eda Y, Sugiwura T., Tanaka M., Miyagishima T., Saiki I., Minagawa T., Kurosawa M., Itaya T., Miyazaki T. Inhibitory effect of Interleukin-4 on the in vitro growth of Ph-positive acute lymphoblastic leukemia cells. Blood 1991; 78: 1574–80
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjia H. K., McCredie K., Trujillo J., Keating M., Gutterman J. U. Therapy of chronic myelogenous leukemia. Cancer 1987; 59: 664–7
   PubMed Web of Science ®Google Scholar
• Roth M. S., Foon K. A. Current states of interferon therapy in oncology. Progress in Hematology 1987; 15: 19–38
   PubMedGoogle Scholar
• Murohashi I., Tohda S., Suzuki T., Nagata K., Yamashita Y., Nara N. Mechanism of action of interleukin 1 on the progenitors of blast cells of acute myeloblastic leukemia. Experimental Hematology 1990; 18: 133–7
   PubMed Web of Science ®Google Scholar
• Salem M. D., Delwel R., Touw I., Mahmoud L. A., Elbasousy E. M., Lowenberg B. Modulation of colony stimulating factor (CSF) dependent growth of acute myeloid leukemia by tumor necrosis factor. Leukemia 1990; 4: 37–43
   PubMed Web of Science ®Google Scholar
• Nara T., Tohda S., Nagata K., Suzuki T., Yamashita Y. Inhibition of the in vitro growth of blast progenitors from acute myeloblastic leukemia patients by transforming growth factor-(TGF-). Leukemia 1989; 3: 572–7
   PubMed Web of Science ®Google Scholar
• Miyauchi J., Wang C., Kelleher C. M., Womg G. G., Clark S. C., Minden M. D., McCulloch E. A. The effects of recombinant CSF-1 on the blast cells of acute myeloblastic leukemia in suspension culture. Journal of Cellular Physiology 1988; 135: 55–62
   PubMed Web of Science ®Google Scholar
• Tepper R. I., Pattengale P. K., Leder P. Murine interleukin-4 displays anti-tumor activity in vivo. Cell 1989; 57: 503–12
   PubMed Web of Science ®Google Scholar
• Taylor C. W., Grogan T. M., Salmon S. E. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma neoplasms. Blood 1990; 75: 1114–8
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Tatsuda T., Taga T., Horii Y., Iwata K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988; 332: 83–5
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechackzyck M., Bataille R. Paracrine rather tan autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517–26
   PubMed Web of Science ®Google Scholar
• Hermann F., Andreeff M., Gruss H.-J., Brach M. A., Lubbert M., Mertelsmann R. Interleukin-4 inhibits growth of multiple myeloma by suppressing interleukin-6 expression. Blood 1991; 78: 207
   Google Scholar
• Akashi K., Harada M., Shibuya T., Eto T., Takamatsu Y., Teshima T., Niho Y. Effects of interleukin-4 and interleukin-6 on the proliferation of CD34+ and CD34+ blasts from acute myelogenous leukemia. Blood 1991; 78: 197–204
   PubMed Web of Science ®Google Scholar
• Hermans A., Heistekamp N., von Linden M., van Baal S., Meijer D., van der Plas D., Wiedmann L. M., Groffen J., Bootsma D., Grosveld G. Unique fusion of bcr, c-abl genes in Philadelphia positive acute lymphoblastic leukemia. Cell 1987; 51: 33–44
   PubMed Web of Science ®Google Scholar
• Okabe M., Matsushima S., Morioka M., Kobayashi M., Abe S., Sakurada K., Kakinuma M., Miyazaki T. Establishment and characterization of a cell line, TOM-1, derived from a patient with Philadelphia chromosome-positive acute lymphocytic leukemia. Blood 1987; 75: 990–8
   Google Scholar
• Okamura J., Yamada S., Ishii E., Hara T., Takahira H., Nishimura J., Yumura K., Kawa-Ha K., Takase K., Enomoto Y., Takase H. A novel leukemia cell line, MR-87, with positive Philadelphia chromosome and negative breakpoint cluster region rearrangement coexpressing myeloid and Early B-cell markers. Blood 1988; 11: 1261–8
   Google Scholar
• Bartram T., Janssen J. W. G., Becher R., De Klein A., Grosveld G. Persistence of chronic myelocytic leukemia despite deletion of rearranged bcr/c-able sequences in blast crisis. The Journal of Experimental Medicine 1986; 164: 1389–96
   PubMed Web of Science ®Google Scholar
• Hart P. H., Vitti G. F., Burgess D. R., Whitty G. A., Piccoli D. S., Hamilton A. J. Potential antiinflammatory effects of interleukin 4: Suppression of human monocyte tumor necrosis factor, interleukin 1, and prostaglandin E2. Proceedings of National Academy Sciences USA 1989; 86: 3903–7
   Web of Science ®Google Scholar
• Grusby M. J., Nabavi N., Wong H., Dick R. F., Bluestone J. A., Schotz M. C., Glimcher L. H. Cloning of an interleukin-4 inducible gene from cytotoxic T lymphocytes and its identification as a lipase. Cell 1990; 60: 451–9
   PubMed Web of Science ®Google Scholar
• Tigges M. A., Casey L. S., Merle-Beral H., Banchereau J., Debre P., Galanaud P. Modulation of different outcomes by a signal receptor and transduction pathway. Science 1989; 243: 781–6
   PubMed Web of Science ®Google Scholar
• London L., McKearn J. P. The dual regulatory role of interleukin 4 is mediated through a direct effect on the target cell. Experimental Hematology 1990; 18: 1059–63
   PubMed Web of Science ®Google Scholar
• Daley G. Q., Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proceedings of National Academy Sciences USA 1988; 85: 9312–16
   PubMed Web of Science ®Google Scholar
• Hariharan I. K., Adams J. M., Cory S. bcr-abl Oncogene renders myeloid cell line factor independent: Potential autocrine mechanism in chronic myeloid leukemia. Oncogene Research 1988; 3: 387–99
   PubMedGoogle Scholar
• Koyasu K., Tojo A., Miyajima A., Akiyama T., Kasuga M., Urabe A., Schreurs J., Arai K., Takaku F., Yahara I. Interleukin 3-specific tyrosine phosphorylation of a membrane glycoprotein of Mr 150,000 in multi-factor dependent cell line. EMBO Journal 1987; 6: 3979–84
   PubMed Web of Science ®Google Scholar
• Isfort R. J., Stevens D., May W. S., Ihle J. N. Interleukin 3 binds to a 140-KDa phosphotyrosine-containing cell surface protein. Proceedings of National Academy Sciences USA 1988; 85: 7982–6
   PubMed Web of Science ®Google Scholar
• Laneuville P., Heisterkamp N., Groffen J. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line. Oncogene 1991; 6: 275–82
   PubMed Web of Science ®Google Scholar